Acrivon Therapeutics, Inc. (ACRV) Stock Price & Analysis
Acrivon Therapeutics, Inc. (ACRV) — MoonshotScore 30/100 (Weak band), calculated Nov 18, 2026. Price $1.40 (-10.26%), as of the Nov 19, 2026 trading session; market cap $60.1M.
Educational signal · not a buy or sell recommendation · How to read this
Acrivon Therapeutics, Inc. · ACRV · NASDAQ
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oncology medicines. Their precision medicine platform aims to identify patients most likely to respond to their drug candidates.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Acrivon Therapeutics (ACRV)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality, weak growth and an expensive valuation, though the balance sheet is only middling. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Okay; Valuation: Bubble; Growth Durability: Fading; Momentum: Quiet.
Earnings yield is the main valuation drag relative to sector peers.
- EPS beat 0 of the last 4 reports
- Altman Z -5.03 · Piotroski F 2
- ROE -70.1% · ROA -74.9% · current ratio 7.99 · earnings yield -122.3%
Holding back: weak fundamentals, a rich price
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 30 | Weak | |
| 30 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.40 | |
| Change on the day | -10.26% | |
| Market capitalisation | $60.1M | — |
| Price / earnings (trailing) | -0.83 | |
| Shares traded on the day | 371.4K |
Price & events
Other perspectives
Council score for Acrivon Therapeutics (ACRV): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Acrivon Therapeutics (ACRV), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Acrivon Therapeutics, Inc. (ACRV) is listed on NASDAQ. It employs 74 people. The market values it at $60.1M.
What do the latest results show for Acrivon Therapeutics (ACRV)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
What are the financial strengths and risks for Acrivon Therapeutics (ACRV)?
Short answer · as of
What is holding it back is weak fundamentals, a rich price. The distress and quality screens read Altman Z -5.03 · Piotroski F 2. Trailing ratios: ROE -70.1% · ROA -74.9% · current ratio 7.99 · earnings yield -122.3%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -5.03 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-70.1%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
What should you watch next at Acrivon Therapeutics (ACRV)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $1.50M · EPS -1.83 · 5 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No quarterly income statement is held for ACRV.
Checked against the records this page reads, on the dates shown above.
How does Acrivon Therapeutics compare with its peers?
Short answer
Acrivon Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.07 Nov 19, 2026 | $540M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $12.17 Nov 19, 2026 | $861M | 69 5-pillar Nov 18, 2026 | |
| $9.28 Nov 19, 2026 | $545M | 68 5-pillar Nov 18, 2026 | |
| $30.78 Nov 19, 2026 | $1.03B | 64 5-pillar Nov 18, 2026 | |
| $8.14 Nov 19, 2026 | $796M | 63 5-pillar Nov 18, 2026 | |
| Acrivon Therapeutics (ACRV) — this page | $1.40 | $60.1M | 30 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $1.50M
- EPS estimate
- $-1.83
Measured against a quoted price of $1.40 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 22, 2026
- Transactions
- 20
- Identified insiders
- 14
- Purchases
- 0
- Sales
- 11
- Other transactions
- 9
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ACRV in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ACRV in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Acrivon Therapeutics (ACRV)?
- Acrivon Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
- Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights
- Acrivon Therapeutics, Inc. (ACRV) Discusses ACR-525 Acquisition and PKC Inhibitor Preclinical Program Transcript
- Acrivon Therapeutics Acquires ACR-525 and PKCθ Inhibitor Program from Aqilion AB
Common Questions About ACRV
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for ACRV?
ACRV carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oncology medicines.
Is ACRV a good stock to buy?
Stock Expert AI does not rate ACRV buy, sell or hold. Acrivon Therapeutics, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ACRV stock price today?
The last price recorded for Acrivon Therapeutics, Inc. (ACRV), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key factors to evaluate for ACRV?
Acrivon Therapeutics, Inc. (ACRV) holds a MoonshotScore in the low range. Not financial advice.
How frequently does ACRV data refresh on this page?
ACRV's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ACRV's recent stock price performance?
Acrivon Therapeutics, Inc. (ACRV) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary proteomics-based patient responder identification platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ACRV overvalued or undervalued right now?
Acrivon Therapeutics, Inc. (ACRV) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ACRV?
Fractional-share availability for Acrivon Therapeutics, Inc. (ACRV) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
How can I track ACRV's earnings and financial reports?
Acrivon Therapeutics, Inc. (ACRV) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for ACRV earnings announcements.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 16 figures on this page — 8 from Financial Modeling Prep (FMP), 6 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com